Jump to content

Camostat

From Wikipedia, the free encyclopedia
(Redirected from C20H22N4O5)
Camostat
Clinical data
Trade namesFoipan
Other namesFOY-305
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • US: Not FDA approved
  • In general: ℞ (Prescription only)
Identifiers
  • N,N-Dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)phenylacetate
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H22N4O5
Molar mass398.419 g·mol−1
3D model (JSmol)
  • CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N
  • InChI=1S/C20H22N4O5/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22/h3-10H,11-12H2,1-2H3,(H4,21,22,23) checkY
  • Key:XASIMHXSUQUHLV-UHFFFAOYSA-N checkY
  (verify)

Camostat is a serine protease inhibitor. Serine protease enzymes have a variety of functions in the body, and so camostat has a diverse range of uses. Camostat is approved in Japan for the treatment of chronic pancreatitis and postoperative reflux esophagitis.[1][2] The oral proteolytic enzyme inhibitor has been on the market since 1985 under the trade name Foipan Tablets. The manufacturer is Ono Pharmaceutical. The drug is used in the treatment of some forms of cancer and is also effective against some viral infections, as well as inhibiting fibrosis in liver or kidney disease or pancreatitis.[3][4][5][6][7]

Pharmacology

[edit]

It is an inhibitor of the enzyme transmembrane protease, serine 2 (TMPRSS2). For chronic pancreatitis camostat's typical dose is 600 mg daily, for postoperative reflux esophagitis 300 mg are taken. The daily dose is split in 3 doses and taken after each meal.[1][8]

Side effects

[edit]

As side effects allergic reactions including anaphylaxis, hypersensitivity, hyperkalemia, platelet and leukocyte depletion, liver dysfunction, jaundice have been reported.[9]

COVID-19

[edit]
Camostat 100mg tablets (Japanese Blister)

Inhibition of TMPRSS2 partially blocked infection by SARS-CoV and Human coronavirus NL63 in HeLa cell cultures.[10] Another in vitro study showed that camostat significantly reduces the infection of Calu-3 lung cells by SARS-CoV-2, the virus responsible for COVID-19.[11][12] It is currently in many Phase 1 and Phase 2 clinical trials.[13][14]

Camostat decreased CRP levels better compared to Lopinavir/Ritonavir in a small study of mild COVID-19 patients.[15] Camostat decreased COVID-19 severity, improved inflammatory markers and oxygenation compared to hydroxychloroquine treated patients.[16][12]

A study of 205 COVID-19 patients treated with Camostat, carried out at Aarhus University Hospital in Denmark and concluding in April 2021, showed no noticeable effects of Camostat on duration of hospitalisation or severity of the cases, but noted that higher doses (the study used 600 mg Camostat daily dosage) might still have a possible effect.[17]

On July 1, 2021, the AIDS Clinical Trials Group announced that the Camostat group on the "ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial" would not be moving forward to Phase 3. The trial demonstrated no safety concerns but also no changes in viral shedding or symptom improvement.[18]

References

[edit]
  1. ^ a b "FOIPAN® Tablets 100mg" (PDF). Ono Pharmaceutical Co., Ltd.
  2. ^ "Camostat". drugs.com.
  3. ^ Okuno M, Kojima S, Akita K, Matsushima-Nishiwaki R, Adachi S, Sano T, et al. (January 2002). "Retinoids in liver fibrosis and cancer". Frontiers in Bioscience. 7 (4): d204–d218. doi:10.2741/A775. PMID 11779708.
  4. ^ Hsieh HP, Hsu JT (2007). "Strategies of development of antiviral agents directed against influenza virus replication" (PDF). Current Pharmaceutical Design. 13 (34): 3531–3542. doi:10.2174/138161207782794248. PMID 18220789.
  5. ^ Kitamura K, Tomita K (February 2012). "Proteolytic activation of the epithelial sodium channel and therapeutic application of a serine protease inhibitor for the treatment of salt-sensitive hypertension". Clinical and Experimental Nephrology. 16 (1): 44–48. doi:10.1007/s10157-011-0506-1. PMID 22038264. S2CID 6522071.
  6. ^ Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R, Nunneley JW, et al. (April 2015). "Protease inhibitors targeting coronavirus and filovirus entry". Antiviral Research. 116: 76–84. doi:10.1016/j.antiviral.2015.01.011. PMC 4774534. PMID 25666761.
  7. ^ Ueda M, Uchimura K, Narita Y, Miyasato Y, Mizumoto T, Morinaga J, et al. (2015). "The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects". Nephron. 129 (3): 223–232. doi:10.1159/000375308. PMID 25766432. S2CID 207652863.
  8. ^ Breining P, Frølund AL, Højen JF, Gunst JD, Staerke NB, Saedder E, Cases-Thomas M, Little P, Nielsen LP, Søgaard OS, Kjolby M (February 2021). "Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety". Basic & Clinical Pharmacology & Toxicology. 128 (2): 204–212. doi:10.1111/bcpt.13533. PMID 33176395.
  9. ^ "医療用医薬品 : カモスタットメシル酸塩 (カモスタットメシル酸塩錠100mg「日医工」)". KEGG (in Japanese). Retrieved 2021-02-05.
  10. ^ Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S (June 2012). "Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry". Journal of Virology. 86 (12): 6537–6545. doi:10.1128/JVI.00094-12. PMC 3393535. PMID 22496216.
  11. ^ Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. (April 2020). "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor". Cell. 181 (2): 271–280.e8. doi:10.1016/j.cell.2020.02.052. PMC 7102627. PMID 32142651.
  12. ^ a b Jackson CB, Farzan M, Chen B, Choe H (January 2022). "Mechanisms of SARS-CoV-2 entry into cells". Nature Reviews. Molecular Cell Biology. 23 (1): 3–20. doi:10.1038/s41580-021-00418-x. PMC 8491763. PMID 34611326.
  13. ^ Clinical trial number NCT04374019 for "Novel Agents for Treatment of High-risk COVID-19 Positive Patients" at ClinicalTrials.gov
  14. ^ "Search of: camostat - covid - List Results". ClinicalTrials.gov. Retrieved 2021-02-04.
  15. ^ Choi JP, Kim HJ, Han J, Park S, Han J (2020-12-15). Foistar(Camostat mesylate) associated with the significant decrease in CRP levels compared to Kaletra(Lopinavir/Ritonavir) treatment in Korean mild COVID-19 pneumonic patients (Report). Infectious Diseases (except HIV/AIDS). doi:10.1101/2020.12.10.20240689.
  16. ^ Hofmann-Winkler H, Moerer O, Alt-Epping S, Bräuer A, Büttner B, Müller M, et al. (November 2020). "Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation". Critical Care Explorations. 2 (11): e0284. doi:10.1097/CCE.0000000000000284. hdl:20.500.11850/460814. PMC 7671878. PMID 33225308.
  17. ^ "Middel mod halsbrand bremsede ikke Covid-19". newsroom.au.dk (in Danish). Retrieved 2021-04-28.
  18. ^ "ACTG announces Camostat will not advance to phase 3 in outpatient treatment study for COVID-19". EurekAlert!. Retrieved 2021-07-01.
[edit]
  • Kunze H, Bohn E (May 1983). "Effects of the serine protease inhibitors FOY and FOY 305 on phospholipase A1 (EC 3.1.1.32) activity in rat - liver lysosomes". Pharmacological Research Communications. 15 (5): 451–459. doi:10.1016/S0031-6989(83)80065-4. PMID 6412250.
  • Göke B, Stöckmann F, Müller R, Lankisch PG, Creutzfeldt W (1984). "Effect of a specific serine protease inhibitor on the rat pancreas: systemic administration of camostate and exocrine pancreatic secretion". Digestion. 30 (3): 171–178. doi:10.1159/000199102. PMID 6209186.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Camostat&oldid=1209237581"